3. MS Treatments & Medications

Good news for those on Ocrevus - longer-term data presented at the 2026 AAN meeting showed that at week 96, 96.7% of study participants were relapse-free, with disability scores remaining stable. Encouraging results for a widely used DMT.

Article here: https://mymsaa.org/news/whats-new-in-ms-research-may-2026/